Globus Medical (NYSE: GMED) reported Q4 EPS of $0.43, $0.04 better than the analyst estimate of $0.39. Revenue for the quarter came in at $195.9 million versus the consensus estimate of $191.33 million.

“Our fourth quarter and full year results are indicative of strong momentum in several key strategic areas,” said Dave Demski, CEO. “The fourth quarter marked the fifth consecutive quarter of double digit organic revenue growth, which is particularly outstanding considering the strong comparable quarter last year. Emerging Technologies delivered $14.7 million, or 34.1% growth, a significant accomplishment given the pent up demand implicit in the fourth quarter of 2017 when we launched our robotic system. The U.S. spinal implant business grew by over 9.4% year-over-year, continuing the acceleration we saw in the third quarter, driven by robotic implant pull through and strong recruiting.”

GUIDANCE:

Globus Medical sees FY2019 EPS of $1.72, versus the consensus of $1.72. Globus Medical sees FY2019 revenue of $770 million, versus the consensus of $766.1 million.

For earnings history and earnings-related data on Globus Medical (GMED) click here.